Carlo Rizzuto, Ph.D., is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (sale), Repare (2020 IPO), Century Therapeutics (2021 IPO), Graphite Bio (2021 IPO), Jnana, 858 Therapeutics and Stablix. Carlo has been instrumental in establishing Versant’s presence in the Northeast. Prior to opening the NYC office, he was based in Versant’s Basel office.
Carlo joined Versant from Novartis where he led global product development teams advancing innovative new medicines. Prior to his role at Novartis, he held the position of Associate Principal with McKinsey & Company, advising U.S. and European clients in the pharmaceutical, payor and provider sectors. Carlo holds a Ph.D. in virology from Harvard University.